At a glance
ClinicalIndex Comparison RecordN/ACompleted· 214 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Posaconazole 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole
In Brief
An observational study evaluating Posaconazole for Mycoses. Completed, enrolled 214 participants.
Detailed Summary
The purpose of this postmarketing surveillance study is to collect an extensive body of data in a large patient population in every day life to investigate the safety and efficacy of NOXAFIL® (posaconazole) in the treatment of invasive fungal disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMycoses
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
Primary CompletionJul 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago
Interventions
Posaconazoledrug
The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.